Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 25, 2013. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to treasury shares.
- Shares Purchased: 1,400,000 Ordinary Shares of 25 pence each.
- Purchase Date: June 25, 2013.
- Price Range: Highest price paid was 1,595 pence per share; lowest price paid was 1,579 pence per share.
- Treasury Holdings (Settled): 513,399,512 shares (9.45% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,039,512 shares (10.52% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,916,777,239 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,400,000 shares for treasury. This action increased the percentage of total voting rights held in treasury from the prior level to 10.52% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (513,399,512 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,916,777,239 shares in issue) for disclosure threshold notifications.
- Review the price paid per share (1,579 to 1,595 pence) to assess the cost of capital relative to market prices on June 25, 2013.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.